News | EP Mapping and Imaging Systems | October 29, 2018

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

Sheath can be visualized on Carto 3 system during catheter ablation to reduce dependence on fluoroscopy

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

October 29, 2018 — Good Samaritan Hospital recently became the first hospital on the West Coast to utilize the Carto Vizigo bi-directional guiding sheath. The sheath can be visualized on the Carto 3 System during a catheter ablation procedure, helping electrophysiologists reduce dependency on fluoroscopy.

A sheath is an introducer routinely used by physicians to facilitate catheter access, stability and tissue contact when targeting sites for catheter ablation to treat arrhythmias. Electrophysiologists rely on fluoroscopy to identify the location of the sheath, therefore requiring use of lead to protect themselves from radiation during the procedure.

According to Ivan Ho, M.D., electrophysiologist practicing at Good Samaritan Hospital and the first to use the technology on the West Coast, the long deflectable sheath has become a major step forward in achieving catheter stability and appropriate radiofrequency energy delivery in complex left-sided arrhythmia ablations. "One of the limitations has been the need of periodic fluoroscopic imaging of the sheath's relative position with the catheter to optimize contact with endocardial surface and ensure safety due to the relatively stiff shaft of these sheaths," said Ho.  The Vizigo allows the direction of the sheath and its relationship with the catheter to be visualized accurately on a 3-D mapping system, minimizing the use of fluoroscopy and overall procedure time.

This new technology is incorporated easily into the physicians' workflow, designed to enhance efficiency during mapping and positioning of the ablation catheter. The smooth tip-to-dilator transition promotes ease of entry into the left atrium during transseptal access, while deflections of 180 degrees in both directions mean increased steerability, which may improve access to hard-to-reach sites.

For more information: www.biosensewebster.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init